TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oncolytics Biotech ( (ONCY) ) has shared an update.
On November 12, 2025, Oncolytics Biotech Inc. released its financial results for the three and nine months ended September 30, 2025. The company reported a net loss of $14.4 million for the third quarter, compared to $9.5 million in the same period last year. The increase in net loss was primarily due to higher general and administrative expenses. Despite the financial challenges, Oncolytics continues to focus on advancing its clinical programs, which are critical to its strategic positioning in the biotech industry.
The most recent analyst rating on (ONCY) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. operates within the biotechnology industry, focusing on developing innovative cancer therapies. The company is known for its work on viral-based therapeutics, particularly targeting oncology markets.
Average Trading Volume: 1,051,252
Technical Sentiment Signal: Hold
Current Market Cap: $108.3M
For an in-depth examination of ONCY stock, go to TipRanks’ Overview page.